At the news
? NEUTRALIMPACT 5/10 8-K filed Nov 9, 2026 at 06:13 ET
Charles River Laboratories announced it has entered definitive agreements to acquire Frontage Holdings Corporation's bioanalysis and DMPK operations in Exton, Pennsylvania for approximately $470 million in cash, plus up to $75 million in contingent earnout payments. The transaction is expected to close in the first half of 2027 and is expected to be neutral to non-GAAP EPS in 2027 and accretive thereafter.
- Purchase price of approximately $470 million in cash for Frontage's bioanalysis and DMPK operations
- Additional contingent payments of up to $75 million based on future performance
- Transaction expected to close during first half of 2027
- Acquired businesses represented approximately 40% of Frontage's total 2025 revenue of $256.7 million
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access